{Reference Type}: Journal Article
{Title}: Kinetic profiling of novel spirobenzo-oxazinepiperidinone derivatives as equilibrative nucleoside transporter 1 inhibitors.
{Author}: Vlachodimou A;Bouma J;De Cleyn M;Berthelot D;Pype S;Bosmans JP;van Vlijmen H;Wroblowski B;Heitman LH;IJzerman AP;
{Journal}: Purinergic Signal
{Volume}: 20
{Issue}: 2
{Year}: 2024 04 10
{Factor}: 3.95
{DOI}: 10.1007/s11302-023-09948-9
{Abstract}: Evaluation of kinetic parameters of drug-target binding, kon, koff, and residence time (RT), in addition to the traditional in vitro parameter of affinity is receiving increasing attention in the early stages of drug discovery. Target binding kinetics emerges as a meaningful concept for the evaluation of a ligand's duration of action and more generally drug efficacy and safety. We report the biological evaluation of a novel series of spirobenzo-oxazinepiperidinone derivatives as inhibitors of the human equilibrative nucleoside transporter 1 (hENT1, SLC29A1). The compounds were evaluated in radioligand binding experiments, i.e., displacement, competition association, and washout assays, to evaluate their affinity and binding kinetic parameters. We also linked these pharmacological parameters to the compounds' chemical characteristics, and learned that separate moieties of the molecules governed target affinity and binding kinetics. Among the 29 compounds tested, 28 stood out with high affinity and a long residence time of 87 min. These findings reveal the importance of supplementing affinity data with binding kinetics at transport proteins such as hENT1.